Glimepiride – CRI Report https://www.cri-report.com market research vender! Thu, 29 Nov 2018 07:08:42 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Glimepiride – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Glimepiride Market, 2018-2022 https://www.cri-report.com/investigation-report-on-chinas-glimepiride-market-2018-2022/ Thu, 29 Nov 2018 06:58:05 +0000 https://www.cri-report.com/product/import-placeholder-for-1811352/ Description Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi’s brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995. Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride…

The post Investigation Report on China’s Glimepiride Market, 2018-2022 first appeared on CRI Report.

]]> Description
Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi’s brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995. Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.
According to CRI, with the development of China’s economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.
According to CRI, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China. The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.’s Amaryl captured more than 80% share of China’s Glimepiride market.
It is expected that as the number of diabetics continues to grow, China’s Glimepiride market will have huge growth potential in the next few years.

Topics Covered:
– Situation of diabetes in China
– Sales of Glimepiride in China
– Competition on China’s Glimepiride market
– Prices of Glimepiride in China
– Forecasts on China’s Glimepiride market from 2018 to 2022

The post Investigation Report on China’s Glimepiride Market, 2018-2022 first appeared on CRI Report.

]]>